title: Effectiveness of an anti-inflammatory drug, loxoprofen, for patients with nocturia.
abstract: OBJECTIVE
  There is increasing evidence that non-steroidal anti-inflammatory drugs are effective for the treatment of nocturia. In this study, we attempted to investigate the role of loxoprofen sodium (loxoprofen) in the therapeutic management of patients with nocturia.
  
  
  METHODS
  Fifteen benign protastatic hyperplasia and/or overactive bladder patients (13 males and 2 females, 71.1 +/- 1.5 years old) with three or more voids per night were involved. These patients had received standard drug therapy. Although these patients had received standard drug therapy for more than half a year, they had still three or more episodes of nocturia. The patients took a single dose of 60 mg of loxoprofen at night prior to sleep. Before and 1 week after the initiation of this therapy, the effects of this treatment were assessed by frequency volume chart and a questionnaire.
  
  
  RESULTS
  In the questionnaire, seven patients answered as excellent, six patients demonstrated improvement of their symptoms, two patients did not show a significant change in their symptoms and no patients demonstrated a deterioration in the symptoms. In frequency volume chart, total void per day, total void per night, total urine volume per day, total night urine volume per day and single voided volume in the night before and after this treatment were 9.97 +/- 0.81 and 8.99 +/- 0.74 per day, 3.82 +/- 0.25 and 1.82 +/- 0.27 per night, 1349 +/- 81 and 1258 +/- 91 mL per day, 567 +/- 46 and 325 +/- 51 mL per night, and 143 +/- 13 and 149 +/- 10 mL, respectively.
  
  
  CONCLUSIONS
  Loxoprofen can be effective and useful for patients with nocturia. Our data suggest that the main mechanism of this effect is to decrease urine production during a night's sleep.
authors.affiliation: Department of Surgery, Division of Urology, Tottori University Faculty of Medicine, Yonago, Japan. saitomo@grape.med.tottori-u.ac.jp
authors.forename: Motoaki
authors.initials: M
authors.lastname: Saito
authors.forename: Masahito
authors.initials: M
authors.lastname: Kawatani
authors.forename: Yukako
authors.initials: Y
authors.lastname: Kinoshita
authors.forename: Keisuke
authors.initials: K
authors.lastname: Satoh
authors.forename: Ikuo
authors.initials: I
authors.lastname: Miyagawa
mesh_terms: D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010666:Phenylpropionates / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; C040656:loxoprofen